Pharmacological profile of TH-142177, a novel orally active AT1-receptor antagonist

Fundamental and Clinical Pharmacology

Volumn 11, Issue 5, 1997, Pages 395-401

  Nozawa, Y ^a   Haruno, A ^a   Oda, N ^a   Yamasaki, Y ^a   Matsuura, N ^a   Miyake, H ^a   Yamada, S ^b   Kimura, R ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Angiotensin II; AT1 receptor; Losartan; Renal hypertensive rats; TH 142177

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; LOSARTAN; NORADRENALIN; SARALASIN; TH 142177; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HEART MUSCLE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION;

EID: 0030867385     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1997.tb00201.x     Document Type: Article

References (24)

1. Arunlakshana O, Schild HO. Some quantitative use of drug antagonism. Br J Pharmocol 1959;14:48-58
2. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 1976;72:248-54
3. Brunner HR, Christen Y, Munafo A, Lee RJ, Waeber B, Nussberger J. Clinical experience with angiotensin II receptor antagonists. Am J Hypertens 1992;12:243S-6S
4. 8-angiotensin II and selective nonpeptide antagonists. Biochem Biophys Res Commun 1990;171:813-7
5. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV et al. Nonpeptide angiotensin II receptor antagonists VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:711-7
6. 1 receptor antagonist. Br J Pharmacol 1995;114:1117-24
7. Dzau VJ, Kopelman RI, Barger AC, Haber E. Renin-specific antibody for study of cardiovascular homeostasis. Science 1980;207:1091-3
8. Gavras H, Gavras I. Angiotensin converting enzyme inhibitors. Properties and side effects. Hypertension 1988;11:II-37-41
9. Hayashi E, Isogai M, Kagawa Y, Takayanagi N, Yamada S. Neosurugatoxin, a specific antagonist of nicotinic acethylcholine receptors. J Neurochem 1984;42:1491-4
10. Hunyady L, Balla T, Call KJ. The ligand binding site of the angiotensin AT1 receptor. Trends Pharmacol Sci 1996;17: 135-40
11. Keiser JA, Ryan MJ, Panek RL, Hodges JC, Sircar I. Pharmacological characterization of CI-996, a new angiotensin receptor antagonist. J Pharmacol Exp Ther 1995;272:963-9
12. Nagura J, Yasuda S, Fujishima K, Yamamoto M, Hui C, Kawano K et al. Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist. Eur J Pharmacol 1995;274:201-11
13. Nozawa Y, Haruno A, Oda N, Yamasaki Y, Matsuura N, Yamada S et al. Angiotensin II receptor subtypes in bovine and human ventricular myocardium. J Pharmacol Exp Ther 1994;270:566-71
14. Ogihara T, Arakawa K, Iimura O, Abe K, Saruta T, Ishii M et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV116. J Hypertens 1994;12:535-8
15. 1-receptor antagonist. Br J Pharmacol 1992;107:1173-80
16. Sato A, Nozawa Y. Alkylglycine derivative with angiotensin II antagonism. Japanese patent 1994;JP 06287182
17. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T et al. Pharmacological profile of a highly potent and long-acting angiotensin n receptor antagonist, 2-ethoxy-l-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-IH-benzimidazole- 7-carbox-ylic acid (CV11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyl-oxy)-ethy12-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biphen yl-4-yl]methyl]-1H-benz-imidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-20
18. Streeten DH, Anderson GH, Freiberg JM, Dalakos TG. Use of angiotensin II antagonist (saralasin) in the recognition of angiotensinogenic hypertension. N Engl J Med 1975;292: 657-62
19. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51
20. Vallotton MB. The renin angiotensin system. Trends Pharmacol Sci 1987;8:69-74
21. Wiest SA, Rampersaud A, Zimmerman K, Steinberg MI. Characterization of distinct angiotensin II binding sites in rat adrenal gland and bovine cerebellum using selective nonpeptide antagonists. J Cardiovasc Pharmacol 1991;17:177-84
22. Williams HG. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-25
23. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR et al. Nonpeptide angiotensin II receptor antagonists VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:718-25
24. Yamada S, Isogai M, Kagawa Y, Takayanagi N, Hayashi E, Tsuji K, Kosuge T. Brain nicotinic acethylcholine receptors. Biochemical characterization by neosurugatoxin. Mol Pharmacol 1985;28:120-7